Ppg Industries, Inc. · NYSE:PPG

Ppg Industries — Investor Presentation (2005)

19 slides from Ppg Industries's investor presentation, 2005

  1. Slide 1: PPG Fine Chemicals Business

    PPG Industries, Inc. Fine Chemicals Business More Than A Source . . . A Resource.

  2. Slide 2: 2004 Financial Summary

    2004 Financial Summary $9.5 Billion in Sales $683 Million Income

  3. Slide 3: Respected on the Street

    Respected on the Street “We believe that PPG is one of the best-managed companies in the chemical industry ” Jim Wilbur Salomon Smith Barney “ PPG is a premier industrial growth company; clearly ‘the best in class’ ” Sergey Vasnetsov Lehman Brothers

  4. Slide 4: Stability

    Stability  120 Years young  Uninterrupted dividends since 1899  Increasing each year since 1960  Over 33,000 Employees  16% employee ownership  Shareholders who know the business  Stakeholders in company performance

  5. Slide 5: Fine Chemicals Business Unit

    Fine Chemicals Business Unit Resources of Fortune 100 Company… Agility of a Business Unit Glass $2.2 B $5.3 B Coatings $2.0 B Chemicals Chlor-Alkali Silicas Optical Products Fine Chemicals

  6. Slide 6: Fine Chemicals Business Unit

    Fine Chemicals Business Unit Custom Products Multi-Client Products  cGMP Manufacturing  Phosgene derivatives  Starting Materials  Acid Chlorides  Advanced  Chloroformates Intermediates  Oxazolodinones  API’s  CDI  Non-cGMP Multi-step  pNPCF  4-Phenyl butanol synthesis  + Many Others

  7. Slide 7: Unique Enabling Skills

    Unique Enabling Skills  Asymmetric Synthesis  Catalytic asymmetric hydrogenation O MeO PPh2  Enzyme resolution MeO PPh2 R O PPh2 R O PPh2  Corey catalytic reduction O  Classical resolution MeOBIPHEP SONIPHOS Asymmetric Ligand Licensed from ROCHE (US 5,488,172) Protease H H OEt + OH O O O CO2Et

  8. Slide 8: Phosgenation

    Phosgenation Phosgene Derivatives O O Cl O R R' R N N O Cl R O Cl O Ureas Chloroformates -Chlorochloroformates O Cl Cl O O N O Phosgene R R' O O R Cl R  Fully integrated  Captive use only Carbonates Oxazolidinones Acid Chlorides  50,000 MT per year O O O O R R' R R R' N O O O O O N Carbamates Py

  9. Slide 9: Unique Enabling Skills

    Unique Enabling Skills  LAH, NaBH4, Vitride®, Borane  World Scale Reduction complexes, DIBAL  Grignard  Organometallic  Alkyl Lithium Reactions Chemistry  Lithium Diisopropylamide OH 1) O3  Ozonolysis 2) NaBH4 OH

  10. Slide 10: Unique Enabling Skills

    Unique Enabling Skills  Excellent track record  Regulatory Expertise  No 483’s from 2002 European audit  No 483’s from unannounced US 2004 audit  Multi-stage Process  Cyanation Development  DMS Alkylations  Friedel-Crafts  Low Temperature (-70 C)

  11. Slide 11: Global Fine Chemical Locations

    Global Fine Chemical Locations Pittsburgh, PA Headquarters Monroeville, PA Barberton, Ohio Sales & R&D Manufacturing La Porte, Texas Pharma Avrillé, France Manufacturing Pharma Manufacturing, Chiba, Japan Sales & R&D Manufacturing, Sales

  12. Slide 12: Global Process Development

    Global Process Development  Avrillé, France  Monroeville, PA, USA  Dedicated R&D staff  Phosgene, hydrogenation, LAH lab  Hydrogenation robots  Screening of organic reactions  Analytical capabilities  NMR, MS/MS, HLPC, GC, IR, electron microscopy, FTIR, X-ray, TGA, DSC, calorimetry

  13. Slide 13: PPG Fine Chemicals Manufacturing Sites

    PPG Fine Chemicals Manufacturing Sites •LaPorte, Texas, USA •Avrillé, France

  14. Slide 14: Compliance – An Absolute

    Compliance – An Absolute  Avrillé: Full Compliance with cGMP Guidelines  DMF Type I and fourteen DMFs Type II, and other EDMF  Frequent audits by major pharma companies  Recent FDA inspections – January 2002 – November 1999 – October 1997  AFSSAPS (French Agency) inspected November 2002

  15. Slide 15: Compliance – An Absolute

    Compliance – An Absolute  Avrillé: Full Compliance with cGMP Guidelines  DMF Type I and fourteen DMFs Type II  Frequent audits by major pharma companies  La Porte: Avrillé Harmonized cGMP Program  Unannounced FDA audits: September 2003 and October 2004 – One Form 483 with 4 minor observations i

  16. Slide 16: Compliance – An Absolute

    Compliance – An Absolute  Avrillé: Full Compliance with cGMP Guidelines  DMF Type I and fourteen DMFs Type II  Frequent audits by major pharma companies  La Porte: Avrillé Harmonized cGMP Program  FDA audits completed September 2003 and October 2004  ISO Certified  Avrillé: 9001 since 1996 

  17. Slide 17: Avrillé, France Facility

    Avrillé, France Facility  50 to 400 L Validated pilot plant  100 to 10,000 L Reactors  FDA-inspected cGMP operations  ISO14000  Low temperature capabilities  World scale metal hydride reductions  Pyrophoric / hazardous reactions  Catalytic hydrogenation  Freeze-drying, spray-drying, microni

  18. Slide 18: La Porte, Texas Facility

    La Porte, Texas Facility  380 to 760 L Validated pilot plant  3,800 to 7,600 L Reactors  Validated cGMP operations  ISO 9002  Flexible multi-purpose design  Fully integrated phosgenation  Catalytic hydrogenation  Engineered for low temperature  Environmentally controlled material handling

  19. Slide 19: In Summary …. PPG Fine Chemicals is

    In Summary …. PPG Fine Chemicals is  Technology driven  Excellent FDA inspection record  Globally located with local presence  Solid process development capabilities  Multi-stage synthesis  Small company environment backed by the stability of PPG Industries

PPG Industries — Investor Presentation (2005) on 6ix